Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Arcadia Biosciences (RKDA) Debt to Equity (2016 - 2023)

Historic Debt to Equity for Arcadia Biosciences (RKDA) over the last 10 years, with Q1 2023 value amounting to $0.0.

  • Arcadia Biosciences' Debt to Equity fell 6090.06% to $0.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $0.0, marking a year-over-year decrease of 6090.06%. This contributed to the annual value of $0.0 for FY2022, which is 1123.95% up from last year.
  • Per Arcadia Biosciences' latest filing, its Debt to Equity stood at $0.0 for Q1 2023, which was down 6090.06% from $0.0 recorded in Q4 2022.
  • Arcadia Biosciences' 5-year Debt to Equity high stood at $0.27 for Q3 2020, and its period low was $0.0 during Q1 2023.
  • In the last 5 years, Arcadia Biosciences' Debt to Equity had a median value of $0.01 in 2019 and averaged $0.04.
  • In the last 5 years, Arcadia Biosciences' Debt to Equity surged by 1034461.86% in 2020 and then tumbled by 9881.67% in 2021.
  • Over the past 5 years, Arcadia Biosciences' Debt to Equity (Quarter) stood at $0.02 in 2019, then skyrocketed by 543.92% to $0.11 in 2020, then plummeted by 98.2% to $0.0 in 2021, then rose by 11.24% to $0.0 in 2022, then tumbled by 60.93% to $0.0 in 2023.
  • Its Debt to Equity stands at $0.0 for Q1 2023, versus $0.0 for Q4 2022 and $0.0 for Q3 2022.